New Registrations
South Africa: May 2026 Pharmaceutical Registration Trends
Forty new pharmaceutical registrations in South Africa in May 2026 signal diverse market activity, with strong generics, oncology, and CNS focus.
South Africa's pharmaceutical market saw 40 new product registrations in May 2026, indicating robust activity in new drug introductions and market expansions. This monthly snapshot provides critical insights into therapeutic trends, key players, and the evolving regulatory landscape.
Overview of New Registrations
The 40 new registrations cover a broad spectrum of therapeutic areas, with a notable emphasis on generics, oncology, diabetes management, and central nervous system (CNS) medications. This diversity reflects both the ongoing need for affordable treatment options and the introduction of innovative therapies.
Key Therapeutic Areas and Products
Analysis of the newly registered products highlights several therapeutic categories experiencing significant growth:
- Oncology: Two distinct strengths of Oxaliplatin (OXINJO 50, OXINJO 100) from Hetero Drugs and one Abiraterone Acetate (PROSABIRAT 500 mg) from Accord Healthcare were registered. This indicates a sustained focus on cancer treatment, likely driven by increasing disease burden and the need for more accessible options.
- Cardiovascular/Anticoagulants: Apixaban generics (APIXABAN 2,5 CIPLA, APIXABAN 5 CIPLA from Cipla Medpro, and PIXULANT 2,5, PIXULANT 5 from Cipla Medpro) stand out. The multiple registrations of different strengths of Apixaban suggest a competitive market for oral anticoagulants and a push for generic penetration in this high-volume area.
- Diabetes Management: Empagliflozin (MEGLYZIN 10) by Hetero Drugs and Metformin Hydrochloride (FORTESE XR 1000 from Ascend Laboratories, ARROW METFORMIN HCL 850 mg from 3Sixty Biopharmaceuticals) were registered. These additions reinforce the ongoing battle against diabetes and the market's demand for various glucose-lowering agents.
- CNS Agents: Betahistine Dihydrochloride (BISTOCHIRA 8, 16, 24) from Evohealth and Gabapentin (ARIPENTIN 400) from 3Sixty Biopharmaceuticals indicate an increased focus on neurological and vestibular disorders. The registration of different strengths of Betahistine suggests a comprehensive approach to managing conditions like Meniere's disease. Older CNS drugs like Dothiepin Hydrochloride (PROTHIADEN 25 mg) also reappeared, likely as renewed registrations or transfers.
- Gastrointestinal: Esomeprazole Magnesium Dihydrate (ATALYD 2,5 GRANULES, ATALYD 5 GRANULES, ESOMEPRAZOLE 2,5 GRANULES CIPLA, ESOMEPRAZOLE 5 GRANULES CIPLA) from Cipla Medpro shows a strong generic presence in proton pump inhibitors, a commonly used class of drugs.
- Anti-Inflammatories/Analgesics: Diclofenac Potassium (SENORAK) from Ruby Pharmaceuticals and multiple Ibuprofen products (BRUFEN 200, BRUFEN 600, BRUFEN FOR CHILDREN, BRUFEN RETARD) and Flurbiprofen (FROBEN SR, FROBEN SYRUP, FROBEN SUPPOSITORIES) from Abbott Laboratories S.A. highlight the persistent demand for pain and inflammation management.
Active Pharmaceutical Companies and Market Dynamics
Several pharmaceutical companies demonstrated significant activity in May 2026:
- Cipla Medpro (Pty) Ltd: Emerges as a highly active player, securing six new registrations for Apixaban and Esomeprazole. This reinforces Cipla's strong position in the South African generics market, particularly in high-demand therapeutic areas like cardiovascular and gastrointestinal.
- Abbott Laboratories S.A. (Pty) Ltd: Showcased a remarkable 12 registrations, primarily focusing on established brands like Brufen (ibuprofen), Isoptin (verapamil), and Froben (flurbiprofen), alongside offerings like Phenylephrine and Prothiaden. This activity might represent re-registrations, line extensions, or transfers, underscoring their commitment to maintaining a broad portfolio.
- Hetero Drugs South Africa (Pty) Ltd: With three new registrations for Oxaliplatin and Empagliflozin, Hetero Drugs is marking its presence in critical areas like oncology and diabetes, consistent with global trends of increased demand for these therapies.
- Evohealth (Pty) Ltd: Registered three strengths of Betahistine, signalling an expansion in CNS or otolaryngological therapeutic segments.
- 3Sixty Biopharmaceuticals (Pty) Ltd: Added two products, Gabapentin and Metformin, indicating investment in both neurological and metabolic health.
The strong presence of generic manufacturers like Cipla Medpro, Hetero Drugs, and others developing generics for established molecules like Apixaban, Empagliflozin, and Esomeprazole suggests increased competition and a continued drive to offer more affordable treatment options. This trend is vital for improving access to medicines in South Africa.
Implications for Market Access and Regulatory Landscape
The high volume of new registrations, particularly generics, has several implications for the South African pharmaceutical market:
- Increased Competition: The introduction of multiple generic versions of key drugs will likely intensify price competition, potentially leading to cost savings for patients and the healthcare system.
- Improved Patient Access: With more options available, particularly for chronic conditions like diabetes and cardiovascular diseases, patient access to essential medicines is expected to improve.
- Regulatory Efficiency: The consistent flow of new registrations indicates an efficient, though perhaps backlogged, regulatory process at SAHPRA (South African Health Products Regulatory Authority). The processing of multiple products from single companies suggests a streamlined review for certain dossiers.
- Strategic Market Entry: Companies are strategically targeting high-value therapeutic areas where there is both significant unmet need and established market pathways for generics.
Detailed List of New Registrations (May 2026)
| Drug | Holder | Country | Status | Date Added |
|---|---|---|---|---|
| OXINJO 100 (each 20,0 ml solution contains: oxaliplatin 100,0 mg) | Hetero Drugs South Africa (Pty) Ltd | South Africa | active | 29 May 2026 |
| SENORAK (each tablet contains: diclofenac potassium 50,0 mg) | Ruby Pharmaceuticals (Pty) Ltd | South Africa | active | 29 May 2026 |
| APIXABAN 2,5 CIPLA (each tablet contains: apixaban 2,5 mg) | Cipla Medpro (Pty) Ltd | South Africa | active | 29 May 2026 |
| MEGLYZIN 10 (each tablet contains: empagliflozin 10,0 mg) | Hetero Drugs South Africa (Pty) Ltd | South Africa | active | 29 May 2026 |
| LINCO- SPECTIN PREMIX (each sachet contains: lincomycin hydrochloride a equivalent to lincomycin 22g, spectinomycin sulphat) | Zoetis South Africa (Pty) Ltd | South Africa | unknown | 29 May 2026 |
| CLINDAMYCIN 300 EQUITY (each capsule contains: clindamycin hydrochloride equivalent to clindamycin 300,0 mg) | Equity Pharmaceutical (Pty) Ltd | South Africa | active | 29 May 2026 |
| OXINJO 50 (each 10,0 ml solution contains: oxaliplatin 50,0 mg) | Hetero Drugs South Africa (Pty) Ltd | South Africa | active | 29 May 2026 |
| PIXULANT 5 (each tablet contains: apixaban 5,0 mg) | Cipla Medpro (Pty) Ltd | South Africa | active | 29 May 2026 |
| APIXABAN 5 CIPLA (each tablet contains: apixaban 5,0 mg) | Cipla Medpro (Pty) Ltd | South Africa | active | 29 May 2026 |
| FRIPNIT 150 mg ODT (each tablet contains: rifapentine 150,0 mg) | Pharma Dynamics (Pty) Ltd | South Africa | active | 29 May 2026 |
| PIXULANT 2,5 (each tablet contains: apixaban 2,5 mg) | Cipla Medpro (Pty) Ltd | South Africa | active | 29 May 2026 |
| PROSABIRAT 500 mg (each tablet contains: abiraterone acetate 500,0 mg) | Accord Healthcare (Pty) Ltd | South Africa | active | 29 May 2026 |
| TRIOMEL N12E (each 100,0 ml contains: glucose solution 27,5 g amino acid solution 14,2 g lipid emulsion 17,5 g) | Adcock Ingram Critical Care (Pty) Ltd | South Africa | active | 28 May 2026 |
| BISTOCHIRA 24 (each tablet contains: betahistine dihydrochloride 24,0 mg) | Evohealth (Pty) Ltd | South Africa | active | 28 May 2026 |
| ATALYD 2,5 GRANULES (each sachet contains: esomeprazole magnesium dihydrate 2,5 mg) | Cipla Medpro (Pty) Ltd | South Africa | active | 28 May 2026 |
| RATHMICOR 150 mg/3 ml (each ampoule contains: amiodarone hydrochloride 150,0 mg) | Austell Pharmaceuticals (Pty) Ltd | South Africa | active | 28 May 2026 |
| ESOMEPRAZOLE 5 GRANULES CIPLA (each sachet contains: esomeprazole magnesium dihydrate 5,0 mg) | Cipla Medpro (Pty) Ltd | South Africa | active | 28 May 2026 |
| ATALYD 5 GRANULES (each sachet contains: esomeprazole magnesium dihydrate 5,0 mg) | Cipla Medpro (Pty) Ltd | South Africa | active | 28 May 2026 |
| LIPOFLEX SPECIAL (each 625,0 ml infusion contains: alanine 4,245 g arginine 2,363 g aspartic acid 1,313 g calcium chlo) | B Braun Medical (Pty) Ltd | South Africa | active | 28 May 2026 |
| BISTOCHIRA 8 (each tablet contains: betahistine dihydrochloride 8,0 mg) | Evohealth (Pty) Ltd | South Africa | active | 28 May 2026 |
| FORTESE XR 1000 (each tablet contains: metformin hydrochloride 1000,0 mg) | Ascend Laboratories (Pty) Ltd | South Africa | active | 28 May 2026 |
| BISTOCHIRA 16 (each tablet contains: betahistine dihydrochloride 16,0 mg) | Evohealth (Pty) Ltd | South Africa | active | 28 May 2026 |
| ESOMEPRAZOLE 2,5 GRANULES CIPLA (each sachet contains: esomeprazole magnesium dihydrate 2,5 mg) | Cipla Medpro (Pty) Ltd | South Africa | active | 28 May 2026 |
| PHENYLEPHRINE HYDROCHLORIDE INJECTION (each i ml contains: phenylephrine hydrochloride a 10 mg) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | unknown | 27 May 2026 |
| ISOPTIN 120 mg (verapamil) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| CALMETTES (valerian) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| BRUFEN 200 (ibuprofen) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| ISOPTIN SR 240 mg (:verapamil 240,0 mg) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| FROBEN SR (flurbiprofen) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| BRUFEN RETARD (ibuprofen) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| BRUFEN 600 (ibuprofen) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| BRUFEN FOR CHILDREN (ibuprofen) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| PROTHIADEN 25 mg (dothiepin hydrochloride) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| FROBEN SYRUP (flurbiprofen) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| FROBEN SUPPOSITORIES (flurbiprofen) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| CITRO-SODA (each 4 g granules contain: citric acid a 702,22 mg.,sodium bicarbonate a 1715,552 mgsodium citrate a) | Adcock Ingram Limited | South Africa | unknown | 27 May 2026 |
| ARIPENTIN 400 (gabapentin) | 3Sixty Biopharmaceuticals (Pty) Ltd | South Africa | active | 27 May 2026 |
| ARROW METFORMIN HCL 850 mg (metformin hydrochloride) | 3Sixty Biopharmaceuticals (Pty) Ltd | South Africa | active | 27 May 2026 |
| COLOFAC 135 mg (mebeverine hydrochloride) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
| METALCAPTASE 150 mg (d-peniccillamine e 150 mg) | Abbott Laboratories S.A. (Pty) Ltd | South Africa | active | 27 May 2026 |
The new pharmaceutical registrations in South Africa for May 2026 paint a clear picture of market evolution: a strong drive for generic penetration in high-demand therapeutic areas, continued investment in oncology and diabetes, and robust activity from both local and multinational players. This dynamic environment is expected to further enhance patient access and competition within the market.
AfriReg Pro helps regulatory teams automate this tracking, providing real-time alerts and in-depth analyses of new pharmaceutical registrations across African markets, enabling proactive strategic planning and competitive intelligence.